

9/03/04

HFW



Please type a plus sign (+) inside this box →




PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<h2 style="text-align: center;">TRANSMITTAL FORM</h2> <p style="text-align: center;">(to be used for all correspondence after initial filing)</p>		Application Number	10/629,313
		Filing Date	July 28, 2003
		First Named Inventor	FREIMER, NELSON B.
		Group Art Unit	1653
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	14	Attorney Docket Number	UCAL-154CIP5
ENCLOSURES (check all that apply)			
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement SB08a Form (11 pgs.) <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 4 References Postcard	Remarks
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Signing Attorney/Agent (Reg. No.)	CAROL L. FRANCIS, 36,513 BOZICEVIC, FIELD & FRANCIS LLP		
Signature			
Date	Sept 1, 2004		
EXPRESS MAIL LABEL NO. EV 462737848 US			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EXPRESS MAIL LABEL NO. EV 462737848 US

INFORMATION DISCLOSURE STATEMENT Address to: Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 	Attorney Docket	UCAL-154CIP5
	First Named Inventor	FREIMER, NELSON B.
	Application Number	10/629,313
	Confirmation No.	7721
	Filing Date	July 28, 2003
	Group Art Unit	1653
	Examiner Name	Not Yet Assigned
	Title: "METHODS OF COMPOSITIONS FOR DIAGNOSING AND TREATING CHROMOSOME- 18p RELATED DISORDERS"	

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

All of the references identified herein were disclosed in the parent applications serial numbers 09/722,544 filed 11/28/2000; serial number 09/236,134 filed 1/22/1999; serial number 09/631,275 filed 8/2/2000; serial number 09/268,992 filed 3/16/1999; and as such, copies thereof are not included pursuant to the provisions of 37 CFR § 1.98(d). Copies of the following references are enclosed for the Examiner's review:

1. GenBank Accession No. D63813 AO Goodwin, et al., 1990. Manic Depressive Illness. Oxford University Press, New York;
2. Dib, C., et al., "A comprehensive genetic map of the human genome based on 5,264 microsatellites", Nature 380 (6570), 152-154 (1996) D18S1140 Chromosomal MNW (Database ID: AFM287WE1);
3. Weissenbach, et al., "A second-generation linkage map of the human genome", Nature 359 (6398), 794-801 (1992) D18S59 Chromosomal MNW (Database ID: HS178XC3); and
4. Shimizu et al., "Expression profile of active genes in human retina," August 1995, EMBL D63813.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. § 102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. UCAL-154CIP5 may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP


Date:

Sept 1, 2004

By:

Carol L. Francis
Carol L. Francis
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
			Application Number	10/629,313
			Filing Date	July 28, 2003
			First Named Inventor	FREIMER, NELSON B.
			Art Unit	1653
Sheet 1 of 11	Examiner Name	Not Yet Assigned		
			Attorney Docket Number	UCAL-154CIP5

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
		US- 4,190,496		06/02/77	Rubenstein <i>et al.</i>	
		US- 4,745,051		05/17/88	Smith <i>et al.</i>	
		US- 4,376,110		03/08/83	David <i>et al.</i>	
		US- 4,656,127		04/07/87	Mundy	
		US- 4,683,202		07/28/87	Mullis	
		US- 4,816,397		03/28/89	Boss <i>et al.</i>	
		US- 4,816,567		03/28/89	Cabilly <i>et al.</i>	
		US- 4,851,331		07/25/89	Vary <i>et al.</i>	
		US- 4,873,191		10/10/89	Wagner <i>et al.</i>	
		US- 4,946,778		08/07/90	Ladner <i>et al.</i>	
		US- 5,075,217		12/24/91	Weber	
		US- 5,364,759		11/15/94	Caskey <i>et al.</i>	
		US- 5,585,089		12/17/96	Queen <i>et al.</i>	
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS						
Examiner Initials'	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ --Number ⁴ --Kind Code ⁵ (if known)				
		WO88/04300	06/16/88	University Patent Inc.		
		WO88/09810	12/15/88	Synthetic Genetics		
		WO89/10134	11/2/89	The Regents of the Univ. of California		
		WO90/11364	10/04/90	University of Patent Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/629,313
		Filing Date	July 28, 2003
		First Named Inventor	FREIMER, NELSON B.
		Group Art Unit	1653
Sheet 2 of 11	Examiner Name		
		Attorney Docket Number	UCAL-154CIP5

		WO91/02087	02/21/91	Bertin & Cie		
		WO92/15712	09/17/92	Molecular Tool Inc.		
		WO95/00669	01/05/95	Pharmacia Biotech AB Baylor College of Medicine		
		WO95/11995	05/04/95	Affymax Tech N.V.		
		WO 97/37043	10/9/97	The Regents of the Univ. of California		
		WO 98/42362	10/1/98	Millennium Pharmaceuticals, Inc. The Regents of the Univ. of California		
		WO 98/42724	10/1/98	Millennium Pharmaceuticals, Inc. The Regents of the Univ. of California		
		WO 99/47535	09/23/99	Millennium Pharmaceuticals, Inc. The Regents of the Univ. of California		

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Accession No. A1737517, Vanderbosch et al., ESTs from uninoculated roots of medicago truncatula (unpublished June 16, 1999)	
		Adams et al., Initial Assessment of Human Gene Diversity and Expression Patterns Based upon 83 Million av Nucleotides of cDNA Sequence, Nature, Vol. 377 (6547 suppl.), pages 3-17.	
		Ahern, H., "Biochemical, Reagent kits offer scientists good return on investment", The Scientist, July 1995, vol. 9, no., 15	
		Altschul, et al., "Basic local alignment search tool", 1990. J. Molec. Biol. 215:403-410	
		Altschul et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs, (1997) Nucleic Acids Res. 25:3389-3402	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/629,313
		Filing Date	July 28, 2003
		First Named Inventor	FREIMER, NELSON B.
		Group Art Unit	1653
		Examiner Name	
Sheet 3 of 11	Attorney Docket Number	UCAL-154CIP5	

	Ausubel P.M. et al., eds., 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc. and John Wiley & sons, Inc., New York, at pp. 6.3.1-6.3.6 and 2.10.3	
	Baron, et al., "Genetic linkage between X-chromosome markers and bipolar affective illness", Nature (1987) 326: 289-292	
	Baron, et al., "Diminished support for linkage between manic depressive illness and X-chromosome markers in three Israeli pedigrees", 1993, Nature Genet. 3,49-55	
	Baron, "Genetic linkage and bipolar affective disorder: progress and pitfalls", Molecular Psychiatry, 2, 200-210 (1997)	
	Been and Cech, "One binding site determines sequence specificity of Tetrahymena pre-rRNA self-splicing, trans-splicing, and RNA enzyme activity", Cell, (1986) 47:207-216	
	Benoist and Chambon, "In vivo sequence requirements of the SV40 early promotor region," 1981, Nature 290:304-310	
	Bertelsen, et al., "A Danish twin study of manic-depressive disorders", Br. J. Psychiat. (1977) 130: 330-351	
	Berrettini, et al., "Chromosome 18 DNA markers and manic-depressive illness: evidence for a susceptibility gene", Proc. Natl. Acad. Sci. USA (1994) 91: 5918-5921	
	Bird, et al., "Single-chain antigen-binding proteins", 1988. Science 242:423-426	
	Bitter, et al., "Expression and secretion vectors for yeast", Methods in Enzymol. 1987153:516-544	
	Blackwood et al., "A locus for bipolar affective disorder on chromosome 4p", Nature Genetics (1996) 12: 427-430	
	Brinster, et al., "Regulation of metallothionein--thymidine kinase fusion plasmids injected into mouse eggs", 1982, Nature 296:39-42	
	Butler, J.E., "The amplified ELISA: principles of and applications for the comparative quantitation of class and subclass antibodies and the distribution of antibodies and antigens in biochemical separates", 1981, Meth. Enzymol. 73:482-523	
	Campbell, et al. "Sheep cloned by nuclear transfer from a cultured cell line", 1996, Nature380:64-66	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/629,313		
		Filing Date	July 28, 2003		
		First Named Inventor	FREIMER, NELSON B.		
		Group Art Unit	1653		
Sheet	4	of	11	Examiner Name	
				Attorney Docket Number	UCAL-154CIP5

	Chien. et al., "The two-hybrid system: a method to identify and clone genes for proteins that interact with a protein of interest", 1991. Proc. Natl. Acad. Sci. USA, 88:9578-9582	
	Cohen et al., "First generation of the physical map of the human genome", C.R. Acad. Sci. (1993) 316:1484-1488	
	Colbere-Garapin, et al., "A new dominant hybrid selective marker for higher eukaryotic cells", 1981, J. Mol. Biol. 150:1-14	
	Cote et al., "Generation of human monoclonal antibodies reactive with cellular antigens", 1983, Proc. Natl. Acad. Sci. USA 80:2026-2030	
	Cole et al., "The ebv-hybridoma technique and its application to human lung cancer", 1985. Monoclonal Antibodies And Cancer Therapy, Alan R. Liss, Inc., pp. 77-96	
	Creighton, 1983, "Proteins: Structures and Molecular Principles," W.H. Freeman & Co., N.Y., pp.34-49	
	Cronin, et al., "Cystic fibrosis mutation detection by hybridization to light-generated DNA probe arrays", 1996, Human Mutation 7:244-255	
	Dib, C., et al., "A comprehensive genetic map of the human genome based on 5,264 microsatellites", Nature 380 (6570), 152-154 (1996) D18S1140 Chromosomal MNW (Database ID: AFM287WE1)	
	Weissenbach, et al., "A second-generation linkage map of the human genome", Nature 359 (6398), 794-801 (1992) D18S59 Chromosomal MNW (Database ID: HS178XC3)	
	Egeland, et al., "Bipolar affective disorders linked to DNA markers on chromosome 11", Nature (1987) 325: 783-787	
	Ewald, H. et al., "Susceptibility loci for bipolar affective disorder on chromosome 18? A review and a study of Danish families", Psychiatric Genetics, (1997) 7, 1-12	
	Freimer and Reus, 1993, in The Molecular and Genetic Basis of Neurological Disease, Rosenberg, et al., BV eds., Butterworths, New York, pp. 951-965	
	Freimer et al., "Genetic mapping using haplotype, association and linkage methods suggests a locus for severe bipolar disorder (BPI) at 18q22-q23", Nature Genetics (1996) 12:436-441	
	Freimer et al., "An approach to investigating linkage for bipolar disorder using large Costa Rican pedigrees". Am. J. Med. Gen. (1996) 67: 254-263	
	Gautier, et al., "Alpha-DNA. IV: Alpha-anomeric and beta-anomeric tetrathymidylates covalently linked to intercalating oxazolopyridocarbazole. Synthesis, physicochemical properties and poly (rA) binding", 1987. Nucl. Acids Res. 15:6625-6641	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/629,313
				Filing Date	July 28, 2003
				First Named Inventor	FREIMER, NELSON B.
				Group Art Unit	1653
Sheet	5	of	11	Examiner Name	
				Attorney Docket Number	UCAL-154CIP5

	GenBank Accession No. D63813 AO Goodwin, et al., 1990. Manic Depressive Illness. Oxford University Press, New York	
	Goodwin, et al., 1990, Manic Depressive Illness, Oxford University Press, New York	
	Gordon, "Transgenic animals", Transgenic Animals, Intl. Rev. Cytol. (1989) 115,171-229	
	Grompe, "The rapid detection of unknown mutations in nucleic acids", Nature Genetics (1993) 5:111-117	
	Gu, et al., "Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting", 1994. Science 265, 103-106	
	Hampson, R. M. et al., "Mapping studies on a pericentric inversion (18) (p11.31 q21.1) in a family with both schizophrenia and learning disability", Am J Human Genetics, 1997, vol. 61, pgs. 1397-1404	
	Harlow and Lane 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York	
	Haseloff and Gerlach, "Simple RNA enzymes with new and highly specific endoribonuclease activities", 1988. Nature, 334:585-591	
	Helene, "The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides", 1991, Anticancer Drug Des., 6(6):569-584	
	Helene, et al., "Control of gene expression by triple helix-forming oligonucleotides. The antigene strategy", 1992, Ann. N.Y. Acad. Sci.. 660:27-36	
	Houghten, et al. "Peptide and nonpeptide lead discovery using robotically synthesized soluble libraries", 1991, Nature 354:84-86	
	Huse, et al., "Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda", 1989, Science 246:1275-1281	
	Huston, et al., "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli", 1988. Proc. Natl. Acad. Sci. USA 85:5879-5883	
	Innis, et al., PCR Protocols: A Guide to Methods and Applications, eds. Academic Press, Inc., New York, 1990	
	Inouye and Inouye, "Up-promoter mutations in the lpp gene of Escherichia coli.", 1985, Nucleic Acids Res. 13:3101-3109	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/629,313		
		Filing Date	July 28, 2003		
		First Named Inventor	FREIMER, NELSON B.		
		Group Art Unit	1653		
Sheet	6	of	11	Examiner Name	
				Attorney Docket Number	UCAL-154CIP5

	Inoue, et al., "Synthesis and hybridization studies on two complementary nona(2'-O-methyl)ribonucleotides," 1987, Nucl. Acids Res. 15:6131-6148	
	Inoue, et al., "Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H", 1987, FEBS Lett. 215:327-330	
	Ishikawa F et al (eds), 1981, Enzyme Immunoassay, Kgalu Shoin, Tokyo	
	Jalanko et al., "Screening for defined cystic fibrosis mutations by solid-phase minisequencing", 1992, Clin. Chem. 38:39-43	
	Janknecht, et al., "Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus", 1991, Proc. Natl. Acad. Sci. USA 88:8972-8976	
	Karlin and Altschul "Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes", (1990) Proc. Natl. Acad. Sci. USA 87:2264-2268	
	Karlin and Altschul, "Applications and statistics for multiple high-scoring segments in molecular sequences", (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877	
	Kelsoe, et al., "Re-evaluation of the linkage relationship between chromosome 11p loci and the gene for bipolar affective disorder in the Old Order Amish", Nature (1989) 342: 238-243	
	Kohler and Milstein. "Continuous cultures of fused cells secreting antibody of predefined specificity", (1975) Nature 256:495-497	
	Kozbor et al., "The production of monoclonal antibodies from human lymphocytes", 1983. Immunology Today 4:72-79	
	Krol et al., "Modulation of eukaryotic gene expression by complementary RNA or DNA sequences", 1988, BioTechniques (6:958-976) or intercalating agents (see, e.g., Zon, 1988, Pharm. Res. 5:539-549	
	Korenberg et al., "Chromosomal localization of human genes for the LDL receptor family member glycoprotein 330 (LRP2) and its associated protein RAP (LRPAP1)". Genomics (1994) 22: 88-93	
	Lakso, et al., "Targeted oncogene activation by site-specific recombination in transgenic mice", 1992, Proc. Natl. Acad. Sci. USA 89:6232-6236	
	Lam, et al. "A new type of synthetic peptide library for identifying ligand-binding activity", 1991. Nature 354:82-84	
	Landegren et al., "A ligase-mediated gene detection technique", 1988, Science 247:1077-1080	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/629,313
		Filing Date	July 28, 2003
		First Named Inventor	FREIMER, NELSON B.
		Group Art Unit	1653
Sheet 7 of 11	Examiner Name		
	Attorney Docket Number	UCAL-154CIP5	

	Lavitrano et al., "Sperm cells as vectors for introducing foreign DNA into eggs: genetic transformation of mice", 1989, Cell 57:717-723	
	Lemaitre. et al., "Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site", 1987, Proc. Natl. Acad. Sci. U.S.A. 84:648-652	
	Letsinger, et al., "Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture", 1989, Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556	
	Levinson and Levitt, 1987, "Schizoaffective mania reconsidered", Am. J. Psychiat. (1987) 144:415-426	
	Lo, "Transformation by iontophoretic microinjection of DNA: multiple integrations without tandem insertions", 1983, Mol. Cell. Biol. 3:1803-1814	
	Logan and Shenk, "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection", 1984, Proc. Natl. Acad. Sci. USA 81:3655-3659	
	Lowy, et al., "Isolation of transforming DNA: cloning the hamster apt gene", 1980, Cell 22:817-823	
	MacKinnon, D. F. et al., "Genetics of manic depressive illness", 1997, Annu. Rev. Neurosci., 20, 355-373	
	McMahon, F. et al., "Linkage of bipolar affective disorder to chromosome 18 makers in a new pedigree series", Am. J. Human Genetics, 1997, vol. 61, pgs. 1397-1404	
	Maggio, E. (ed.), 1980, Enzyme Immunoassay, CRC Press, Boca Raton, FL © 1980	
	Maher, 1992, "DNA triple-helix formation: an approach to artificial gene repressors?", Bioassays 14(12):807-815	
	Maier, et al., 1995, "Linkage analysis between pericentrometric markers on chromosome 18 and bipolar disorder a replication test", Psych. Res. (1995) 59: 7-15	
	McInnes and Freimer, "Mapping genes for psychiatric disorders and behavioral traits", Curr. Opin. Genet. Develop. (1995) 5: 376-381	
	McInnes et al., "A complete genome screen for genes predisposing to severe bipolar disorder in two Costa Rican pedigrees", Proc. Natl. Acad. Science U.S.A. (1996) 93:13060-13065	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/629,313		
		Filing Date	July 28, 2003		
		First Named Inventor	FREIMER, NELSON B.		
		Group Art Unit	1653		
Sheet	8	of	11	Examiner Name	
				Attorney Docket Number	UCAL-154CIP5

	Matsumoto T. & Johnston D.H et al., "Dexamethasone decreases phagocytosis by human trabecular I meshwork cells in situ". Invest Ophthalmol Vis Sci. 1997 Aug; 38(9):1902-7	
	Morrison et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains", (1984) Proc Natl Acad. Sci 81:6851-6855	
	Murray et al., "A comprehensive human linkage map with centimorgan density. Cooperative Human Center (CHLC)". Science (1994) 265: 2049-2054	
	Myers and Miller, "Optimal alignments in linear space", 1988, CABIOS 4:11-17	
	Neuberger. et al., "Recombinant antibodies possessing novel effector functions", 1984, Nature 312:604-608	
	Nickerson et al, "Automated DNA diagnostics using an ELISA-based oligonucleotide ligation assay", 1990, Proc. Natl. Acad. Sci. U.S.A. 87:8923-8927	
	Nuovo. G.J.. 1992, "PCR In Situ Hybridization: Protocols And Applications", Raven Press, NY	
	Orita et al., "Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms", 1989, Proc. Natl. Acad. Sci. USA 86:2766-2770	
	Pastinen et al., "Multiplex, fluorescent, solid-phase minisequencing for efficient screening of DNA sequence variation", 1996, Clin. Chem. 42:1391-1397	
	Pastinen et al. "Minisequencing: a specific tool for DNA analysis and diagnostics on oligonucleotide arrays", 1997, Genome Res. 7:606-614	
	Pauls et al., "Risks of affective illness among first-degree relatives of bipolar I old-order Amish probands", Arch. Gen. Psychiat. (1992) 49: 703-708	
	Pauls, et al., "Linkage analyses of chromosome 18 markers do not identify a major susceptibility locus, for bipolar affective disorder in the Old Order Amish", Am. J. Hum. Genet. (1995) 57: 636-643	
	Platt. "Independent regulation of adipose tissue-specificity and obesity response of the adipin promoter in transgenic mice", 1994. J. Biol. Chem. 269, 28558-28562	
	Rojas et al., "Identification of candidate genes for psychiatric disorders on 18p11", 2002, Molecular Psychiatry 5:389-395	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/629,313
		Filing Date	July 28, 2003
		First Named Inventor	FREIMER, NELSON B.
		Group Art Unit	1653
		Examiner Name	
Sheet 9 of 11	Attorney Docket Number	UCAL-154CIP5	

	Rosenthal, et al., "Toward the validation of RDC schizoaffective disorder", Arch. General Psychiat. AY (1980) 37:804-810	
	Rossi, "Practical ribozymes. Making ribozymes work in cells", 1994, Current Biology 4:469-471	
	Ruther et al, "Easy identification of cDNA clones", 1983, EMBOJ. 2:1791-1794	
	Santerre, et al., "Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells", 1984, Gene 30:147-156	
	Sarin. et al., "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates", 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451	
	Sarver, et al., "Ribozymes as potential anti-HIV-1 therapeutic agents", 1990, Science 247,1222-1225	
	Shimizu-Matsumoto, A. et al., "An expression profile of genes in human retina and isolation of a complementary DNA for a novel rod photoreceptor protein", 1997, Invest. Ophthalmol. Vis. Sci. 38:2576-2585	
	Shimizu-Matsumoto, A. et al., "1996, Isolation and Chromosomal Localization of the Human Conge cGMP El Phosphodiesterase Gamma cDNA (PDE6H)," Genomics, 121-124	
	Shimizu et al., "Expression profile of active genes in human retina," August 1995, EMBL D63813	
	Shumaker et al., "Mutation detection by solid phase primer extension", 1996, Hum. Mutation 7:346-354	
	Smith, et al., "Molecular engineering of the <i>autographa californica</i> nuclear polyhedrosis virus genome: deletion mutations within the polyhedrin gene", 1983, J. Virol. 46:584-593	
	Smithies, et al. "Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination", 1985, Nature 317:230-234	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/629,313		
		Filing Date	July 28, 2003		
		First Named Inventor	FREIMER, NELSON B.		
		Group Art Unit	1653		
Sheet	10	of	11	Examiner Name	
				Attorney Docket Number	UCAL-154CIP5

		Songyang. et al. "SH2 domains recognize specific phosphopeptide sequences", 1993, Cell 72:767-778	
		Stein, et al., "Physicochemical properties of phosphorothioate oligodeoxynucleotides", 1988, Nucl. Acids Res. 16:3209-3221	
		Straub, et al, 1994, "A possible vulnerability locus for bipolar affective disorder on chromosome 21q22.3", Nature Genet. (1994) 8:291-296	
		Szybalska and Szybalski, "Genetics of human cell lines, IV. DNA-mediated heritable transformation of a biochemical trait", 1962. Proc. Natl. Acad. Sci. USA 48:2026-2039	
		Takeda, et al., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences", 1985 Nature 314:452-454	
		Thomas and Capecchi, "Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells", 1987, Cell 51:503-512	
		Thompson, et al., "Germ line transmission and expression of a corrected HPRT gene produced by gene targeting in embryonic stem cells", 1989, Cell 56:313-321	
		Van Heeke and Schuster, "Expression of human asparagine synthetase in Escherichia coli ", 1989, J. Biol. Chem. 264:5503-5509	
		Van der Putten, et al., "Efficient insertion of genes into the mouse germ line via retroviral vectors", 1985, Proc. Natl. Acad. Sci., USA 82:6148-6152	
		Voller. A. et al., "Enzyme immunoassays with special reference to ELISA techniques", 1978, J. Clin. Pathol. 31:507-520	
		Voller, A., "The Enzyme Linked Immunosorbent Assay (ELISA)", 1978, Diagnostic Horizons 2:1-7, EW Microbiological Associates Quarterly Publication, Walkersville, MD	
		Wagner, et al., "Nucleotide sequence of the thymidine kinase gene of herpes simplex virus type 1", 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445	
		Ward, et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli", 1989. Nature 334:544-546	
		Weintraub, B., Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, March, 1986	
		Wigler. et al., "Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells", 1977, Cell 11:223-232	
		Smithies, et al. "Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination", 1985, Nature 317:230-234	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/629,313		
		Filing Date	July 28, 2003		
		First Named Inventor	FREIMER, NELSON B.		
		Group Art Unit	1653		
Sheet	11	of	11	Examiner Name	
				Attorney Docket Number	UCAL-154CIP5

		Wigler, et al., "Transformation of mammalian cells with an amplifiable dominant-acting gene", 1980, Proc. Natl. Acad. Sci. USA 77:3567-3570	
		Wilmot, et al., "Viable offspring derived from fetal and adult mammalian cells", 1997, Nature 385:810-813	
		Wildenauer, D. B. et al., "Do schizophrenia and affective disorder share susceptibility genes?", Psychiatric Genetics, 1997, vol. 7, pgs. 1-12.	
		Yamamoto, et al., "Identification of a functional promoter in the long terminal repeat of Rous sarcoma virus", 1980, Cell 22:787-797	
		Yoshikawa et al., "Isolation of chromosome 18-specific brain transcripts as positional candidates for bipolar disorder", 1997, Am J Medical Genetics (Neuropsychiatric Genetics) 74:140-149.	
		Young et al., "Evidence that a locus for familial high myopia maps to chromosome 18p", 1998, American Journal of Human Genetics 63:109-119	
		Zaug, et al., "A labile phosphodiester bond at the ligation junction in a circular intervening sequence RNA", 1984, Science, 224:574-578	
		Zaug and Cech, "The intervening sequence RNA of Tetrahymena is an enzyme", 1986. Science, 231:470-475	
		Zaug, et al., "The Tetrahymena ribozyme acts like an RNA restriction endonuclease", 1986, Nature. 324:429-433	
		Zon, "Oligonucleotide analogues as potential chemotherapeutic agents", 1988, Pharm Res 5-539-549	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.